HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase.

Abstract
Pathological angiogenesis in the retina is a leading cause of serious vision loss in potentially blinding eye diseases, including proliferative diabetic retinopathy, retinopathy of prematurity and the wet form of age-related macular degeneration. Hypoxia is thought to be the driver of pathological angiogenesis, and transcription factors such as hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF) are key mediators in these processes. Current treatments employ either laser photocoagulation or intravitreal injection of therapeutic antibodies for VEGF, in order to arrest the growth of leaky blood vessels in the avascular vitreous cavity and to restore visual acuity. However, all such therapeutic approaches are limited by low or variable efficacy, and the inconvenience, risk and financial burden of such treatments, which need to be given frequently. The lack of noninvasive and efficacious therapy has therefore driven the search for alternative strategies. We have been interested in the roles of reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, which when produced intracellularly at low concentration can act as second messengers to regulate physiological and pathological angiogenesis. Accumulating evidence suggests NADPH oxidase-dependent ROS are involved in regulation of the angiogenic signalling pathways of HIF and VEGF. Suppressing pathological neovascularisation in the retina by manipulating such redox mechanisms appears to be an attractive and clinically translatable therapeutic strategy to treat proliferative neovascular eye diseases. Here we provide a brief overview of the roles of NADPH oxidase in the sensing and regulation processes involving HIF and VEGF that contribute to the development of pathological angiogenesis in the retina.
AuthorsElsa C Chan, Guei-Sheung Liu, Gregory J Dusting
JournalCurrent pharmaceutical design (Curr Pharm Des) Vol. 21 Issue 41 Pg. 5988-98 ( 2015) ISSN: 1873-4286 [Electronic] United Arab Emirates
PMID26510439 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Hypoxia-Inducible Factor 1
  • Reactive Oxygen Species
  • Vascular Endothelial Growth Factor A
  • NADPH Oxidases
Topics
  • Humans
  • Hypoxia-Inducible Factor 1 (metabolism)
  • NADPH Oxidases (metabolism)
  • Neovascularization, Pathologic (metabolism)
  • Oxidation-Reduction
  • Reactive Oxygen Species (metabolism)
  • Retina (metabolism, pathology)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: